- Home
- EE vs GERN Comparison
EE vs GERN Comparison
Compare EE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- GERN
- Stock Information
- Founded
- EE 2003
- GERN 1990
- Country
- EE United States
- GERN United States
- Employees
- EE N/A
- GERN N/A
- Industry
- EE Oil/Gas Transmission
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- EE Utilities
- GERN Health Care
- Exchange
- EE Nasdaq
- GERN Nasdaq
- Market Cap
- EE 941.7M
- GERN 853.5M
- IPO Year
- EE 2022
- GERN 1996
- Fundamental
- Price
- EE $28.11
- GERN $1.57
- Analyst Decision
- EE Hold
- GERN Buy
- Analyst Count
- EE 6
- GERN 9
- Target Price
- EE $31.17
- GERN $5.13
- AVG Volume (30 Days)
- EE 361.1K
- GERN 13.0M
- Earning Date
- EE 05-07-2025
- GERN 05-07-2025
- Dividend Yield
- EE 0.85%
- GERN N/A
- EPS Growth
- EE 37.63
- GERN N/A
- EPS
- EE 1.53
- GERN N/A
- Revenue
- EE $966,414,000.00
- GERN $116,293,000.00
- Revenue This Year
- EE $27.78
- GERN $160.12
- Revenue Next Year
- EE $26.19
- GERN $55.01
- P/E Ratio
- EE $18.41
- GERN N/A
- Revenue Growth
- EE N/A
- GERN 22264.04
- 52 Week Low
- EE $16.75
- GERN $1.17
- 52 Week High
- EE $32.99
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- EE 49.65
- GERN 51.71
- Support Level
- EE $28.21
- GERN $1.30
- Resistance Level
- EE $29.53
- GERN $1.54
- Average True Range (ATR)
- EE 0.79
- GERN 0.11
- MACD
- EE -0.06
- GERN 0.03
- Stochastic Oscillator
- EE 4.76
- GERN 66.67
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.